Oscar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oscar Health, Inc. on February 6, 2026. The filing primarily reports the entry into a material definitive agreement regarding a new credit facility and references the announcement of financial results for the fourth quarter and full year ended December 31, 2025, which was issued on February 10, 2026.
Key Financial Metrics and Debt Structure
The filing details the establishment of a new $475.0 million secured three-year revolving credit facility, maturing on February 6, 2029. Key terms include:
- Capacity: $475.0 million with an expansion option for an additional $100.0 million.
- Interest Rates: Initially Term SOFR + 4.50% or Alternate Base Rate + 3.50%. Margins will adjust based on the Total Net Leverage Ratio after June 30, 2026.
- Fees: Initial commitment fee of 0.50% on undrawn amounts, adjustable to a range of 0.35% to 0.50% based on leverage.
- Guarantees: Guaranteed by all wholly owned subsidiaries and future direct/indirect subsidiaries.
- Financial Covenants (2026):
- Direct Policy Premiums must not be less than $3.0 billion per fiscal quarter.
- Liquidity (unrestricted cash + undrawn facility) must not be less than $200.0 million, with at least $100.0 million in unrestricted cash.
- Consolidated Adjusted EBITDA must meet certain thresholds (specific values not provided in text).
- Financial Covenants (2027 onwards):
- Maximum Total Net Leverage Ratio of 3.50:1.00.
- Minimum Fixed Charge Coverage Ratio of 3.00:1.00.
The filing references a press release (Exhibit 99.1) for specific revenue, profit, and cash flow figures for the period ended December 31, 2025, but does not contain those specific numerical values within the text of this 8-K.
Material Changes and Outlook
The primary material change is the restructuring of the company's liquidity position through the new credit facility. The agreement includes standard events of default, including certain changes of control. The filing notes that the company announced its Q4 and full-year 2025 results on February 10, 2026, but the specific operational results, guidance, and management commentary are contained in the referenced press release and are not detailed in this document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 revenue, profit, and cash flow figures.
- Verify the company's current Total Net Leverage Ratio to determine applicable interest margins and commitment fees post-June 30, 2026.
- Confirm compliance with the $3.0 billion quarterly Direct Policy Premiums covenant for the quarter ending March 31, 2026.
- Assess the company's current unrestricted cash balance to ensure it meets the $100.0 million minimum liquidity requirement.
- Examine the full Credit Agreement (Exhibit 10.1) for detailed definitions of "Consolidated Adjusted EBITDA" and specific thresholds.